1. Home
  2. AFMD vs BIVI Comparison

AFMD vs BIVI Comparison

Compare AFMD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • BIVI
  • Stock Information
  • Founded
  • AFMD 2000
  • BIVI 2013
  • Country
  • AFMD Germany
  • BIVI United States
  • Employees
  • AFMD N/A
  • BIVI N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • BIVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • AFMD Health Care
  • BIVI Health Care
  • Exchange
  • AFMD Nasdaq
  • BIVI Nasdaq
  • Market Cap
  • AFMD 55.6M
  • BIVI 45.1M
  • IPO Year
  • AFMD 2014
  • BIVI N/A
  • Fundamental
  • Price
  • AFMD $3.65
  • BIVI $3.25
  • Analyst Decision
  • AFMD Strong Buy
  • BIVI Strong Buy
  • Analyst Count
  • AFMD 5
  • BIVI 2
  • Target Price
  • AFMD $16.25
  • BIVI $40.00
  • AVG Volume (30 Days)
  • AFMD 98.0K
  • BIVI 16.9M
  • Earning Date
  • AFMD 11-14-2024
  • BIVI 11-13-2024
  • Dividend Yield
  • AFMD N/A
  • BIVI N/A
  • EPS Growth
  • AFMD N/A
  • BIVI N/A
  • EPS
  • AFMD N/A
  • BIVI N/A
  • Revenue
  • AFMD $7,959,927.00
  • BIVI N/A
  • Revenue This Year
  • AFMD N/A
  • BIVI N/A
  • Revenue Next Year
  • AFMD $48.98
  • BIVI N/A
  • P/E Ratio
  • AFMD N/A
  • BIVI N/A
  • Revenue Growth
  • AFMD N/A
  • BIVI N/A
  • 52 Week Low
  • AFMD $2.92
  • BIVI $1.04
  • 52 Week High
  • AFMD $8.95
  • BIVI $58.20
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 55.19
  • BIVI 62.20
  • Support Level
  • AFMD $3.63
  • BIVI $2.46
  • Resistance Level
  • AFMD $3.98
  • BIVI $3.61
  • Average True Range (ATR)
  • AFMD 0.24
  • BIVI 0.34
  • MACD
  • AFMD 0.04
  • BIVI 0.07
  • Stochastic Oscillator
  • AFMD 55.65
  • BIVI 68.36

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: